Evaluation of teriparatide treatment in adults with osteogenesis imperfecta

Eric Orwoll, Jay Shapiro, Sandra Veith, Ying Wang, Jodi Lapidus, Chaim Vanek, Jan L. Reeder, Tony M. Keaveny, David C. Lee, Mary A. Mullins, Sandesh C S Nagamani, Brendan Lee

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background. Adults with osteogenesis imperfecta (OI) have a high risk of fracture. Currently, few treatment options are available, and bone anabolic therapies have not been tested in clinical trials for OI treatment. Methods. 79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial. The primary endpoint was the percent change in areal bone mineral density (aBMD) of the lumbar spine (LS), as determined by dualenergy X-ray absorptiometry. Secondary endpoints included percent change in bone remodeling markers and vertebral volumetric BMD (vBMD) by quantitative computed tomography, estimated vertebral strength by finite element analysis, and self-reported fractures. Results. Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1% ± 1.0% vs. 2.8% ± 1.0% change from baseline; P <0.05) and total hip aBMD (2.6% ± 1.0% vs. -2.4% ± 1.0% change; P <0.001). Vertebral vBMD and strength improved with teriparatide therapy (18% ± 6% and 15% ± 3% change, respectively), but declined with placebo (-5.0% ± 6% and -2.0% ± 3% change; P <0.05 for both comparisons). Serum procollagen type 1 N-terminal propeptide (P1NP) and urine collagen N-telopeptide (NTx) levels increased with teriparatide therapy (135% ± 14% and 64% ± 10% change, respectively). Teriparatide-induced elevation of P1NP levels was less pronounced in severe forms of OI (type III/IV) compared with the milder form (type I). Type I OI patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for those with type III/IV OI. There was no difference in self-reported fractures between the 2 groups. Conclusions. Adults with OI, particularly those with less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as increased hip and spine aBMD, vertebral vBMD, and estimated vertebral strength. Trial registration. Clinicaltrials.gov NCT00131469. Funding. The Osteoporosis Imperfecta Foundation, Eli Lilly and Co., the National Center for Advancing Translational Science (NCATS) at the NIH (grant no. UL1RR024140), and the Baylor College of Medicine General Clinical Research Center (grant no. RR00188).

Original languageEnglish (US)
Pages (from-to)491-498
Number of pages8
JournalJournal of Clinical Investigation
Volume124
Issue number2
DOIs
StatePublished - Feb 3 2014

Fingerprint

Teriparatide
Osteogenesis Imperfecta
Bone Density
Placebos
Spine
Collagen Type I
Therapeutics
Pelvic Bones
Finite Element Analysis
Bone Remodeling
Clinical Medicine
Photon Absorptiometry
Osteoporosis
Hip
Collagen
Tomography
Clinical Trials
Urine
Bone and Bones
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. / Orwoll, Eric; Shapiro, Jay; Veith, Sandra; Wang, Ying; Lapidus, Jodi; Vanek, Chaim; Reeder, Jan L.; Keaveny, Tony M.; Lee, David C.; Mullins, Mary A.; Nagamani, Sandesh C S; Lee, Brendan.

In: Journal of Clinical Investigation, Vol. 124, No. 2, 03.02.2014, p. 491-498.

Research output: Contribution to journalArticle

Orwoll, E, Shapiro, J, Veith, S, Wang, Y, Lapidus, J, Vanek, C, Reeder, JL, Keaveny, TM, Lee, DC, Mullins, MA, Nagamani, SCS & Lee, B 2014, 'Evaluation of teriparatide treatment in adults with osteogenesis imperfecta', Journal of Clinical Investigation, vol. 124, no. 2, pp. 491-498. https://doi.org/10.1172/JCI71101
Orwoll, Eric ; Shapiro, Jay ; Veith, Sandra ; Wang, Ying ; Lapidus, Jodi ; Vanek, Chaim ; Reeder, Jan L. ; Keaveny, Tony M. ; Lee, David C. ; Mullins, Mary A. ; Nagamani, Sandesh C S ; Lee, Brendan. / Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 2. pp. 491-498.
@article{24779fca6fcb429fb26d60c40b46fd07,
title = "Evaluation of teriparatide treatment in adults with osteogenesis imperfecta",
abstract = "Background. Adults with osteogenesis imperfecta (OI) have a high risk of fracture. Currently, few treatment options are available, and bone anabolic therapies have not been tested in clinical trials for OI treatment. Methods. 79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial. The primary endpoint was the percent change in areal bone mineral density (aBMD) of the lumbar spine (LS), as determined by dualenergy X-ray absorptiometry. Secondary endpoints included percent change in bone remodeling markers and vertebral volumetric BMD (vBMD) by quantitative computed tomography, estimated vertebral strength by finite element analysis, and self-reported fractures. Results. Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1{\%} ± 1.0{\%} vs. 2.8{\%} ± 1.0{\%} change from baseline; P <0.05) and total hip aBMD (2.6{\%} ± 1.0{\%} vs. -2.4{\%} ± 1.0{\%} change; P <0.001). Vertebral vBMD and strength improved with teriparatide therapy (18{\%} ± 6{\%} and 15{\%} ± 3{\%} change, respectively), but declined with placebo (-5.0{\%} ± 6{\%} and -2.0{\%} ± 3{\%} change; P <0.05 for both comparisons). Serum procollagen type 1 N-terminal propeptide (P1NP) and urine collagen N-telopeptide (NTx) levels increased with teriparatide therapy (135{\%} ± 14{\%} and 64{\%} ± 10{\%} change, respectively). Teriparatide-induced elevation of P1NP levels was less pronounced in severe forms of OI (type III/IV) compared with the milder form (type I). Type I OI patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for those with type III/IV OI. There was no difference in self-reported fractures between the 2 groups. Conclusions. Adults with OI, particularly those with less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as increased hip and spine aBMD, vertebral vBMD, and estimated vertebral strength. Trial registration. Clinicaltrials.gov NCT00131469. Funding. The Osteoporosis Imperfecta Foundation, Eli Lilly and Co., the National Center for Advancing Translational Science (NCATS) at the NIH (grant no. UL1RR024140), and the Baylor College of Medicine General Clinical Research Center (grant no. RR00188).",
author = "Eric Orwoll and Jay Shapiro and Sandra Veith and Ying Wang and Jodi Lapidus and Chaim Vanek and Reeder, {Jan L.} and Keaveny, {Tony M.} and Lee, {David C.} and Mullins, {Mary A.} and Nagamani, {Sandesh C S} and Brendan Lee",
year = "2014",
month = "2",
day = "3",
doi = "10.1172/JCI71101",
language = "English (US)",
volume = "124",
pages = "491--498",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Evaluation of teriparatide treatment in adults with osteogenesis imperfecta

AU - Orwoll, Eric

AU - Shapiro, Jay

AU - Veith, Sandra

AU - Wang, Ying

AU - Lapidus, Jodi

AU - Vanek, Chaim

AU - Reeder, Jan L.

AU - Keaveny, Tony M.

AU - Lee, David C.

AU - Mullins, Mary A.

AU - Nagamani, Sandesh C S

AU - Lee, Brendan

PY - 2014/2/3

Y1 - 2014/2/3

N2 - Background. Adults with osteogenesis imperfecta (OI) have a high risk of fracture. Currently, few treatment options are available, and bone anabolic therapies have not been tested in clinical trials for OI treatment. Methods. 79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial. The primary endpoint was the percent change in areal bone mineral density (aBMD) of the lumbar spine (LS), as determined by dualenergy X-ray absorptiometry. Secondary endpoints included percent change in bone remodeling markers and vertebral volumetric BMD (vBMD) by quantitative computed tomography, estimated vertebral strength by finite element analysis, and self-reported fractures. Results. Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1% ± 1.0% vs. 2.8% ± 1.0% change from baseline; P <0.05) and total hip aBMD (2.6% ± 1.0% vs. -2.4% ± 1.0% change; P <0.001). Vertebral vBMD and strength improved with teriparatide therapy (18% ± 6% and 15% ± 3% change, respectively), but declined with placebo (-5.0% ± 6% and -2.0% ± 3% change; P <0.05 for both comparisons). Serum procollagen type 1 N-terminal propeptide (P1NP) and urine collagen N-telopeptide (NTx) levels increased with teriparatide therapy (135% ± 14% and 64% ± 10% change, respectively). Teriparatide-induced elevation of P1NP levels was less pronounced in severe forms of OI (type III/IV) compared with the milder form (type I). Type I OI patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for those with type III/IV OI. There was no difference in self-reported fractures between the 2 groups. Conclusions. Adults with OI, particularly those with less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as increased hip and spine aBMD, vertebral vBMD, and estimated vertebral strength. Trial registration. Clinicaltrials.gov NCT00131469. Funding. The Osteoporosis Imperfecta Foundation, Eli Lilly and Co., the National Center for Advancing Translational Science (NCATS) at the NIH (grant no. UL1RR024140), and the Baylor College of Medicine General Clinical Research Center (grant no. RR00188).

AB - Background. Adults with osteogenesis imperfecta (OI) have a high risk of fracture. Currently, few treatment options are available, and bone anabolic therapies have not been tested in clinical trials for OI treatment. Methods. 79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial. The primary endpoint was the percent change in areal bone mineral density (aBMD) of the lumbar spine (LS), as determined by dualenergy X-ray absorptiometry. Secondary endpoints included percent change in bone remodeling markers and vertebral volumetric BMD (vBMD) by quantitative computed tomography, estimated vertebral strength by finite element analysis, and self-reported fractures. Results. Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1% ± 1.0% vs. 2.8% ± 1.0% change from baseline; P <0.05) and total hip aBMD (2.6% ± 1.0% vs. -2.4% ± 1.0% change; P <0.001). Vertebral vBMD and strength improved with teriparatide therapy (18% ± 6% and 15% ± 3% change, respectively), but declined with placebo (-5.0% ± 6% and -2.0% ± 3% change; P <0.05 for both comparisons). Serum procollagen type 1 N-terminal propeptide (P1NP) and urine collagen N-telopeptide (NTx) levels increased with teriparatide therapy (135% ± 14% and 64% ± 10% change, respectively). Teriparatide-induced elevation of P1NP levels was less pronounced in severe forms of OI (type III/IV) compared with the milder form (type I). Type I OI patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for those with type III/IV OI. There was no difference in self-reported fractures between the 2 groups. Conclusions. Adults with OI, particularly those with less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as increased hip and spine aBMD, vertebral vBMD, and estimated vertebral strength. Trial registration. Clinicaltrials.gov NCT00131469. Funding. The Osteoporosis Imperfecta Foundation, Eli Lilly and Co., the National Center for Advancing Translational Science (NCATS) at the NIH (grant no. UL1RR024140), and the Baylor College of Medicine General Clinical Research Center (grant no. RR00188).

UR - http://www.scopus.com/inward/record.url?scp=84893829218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893829218&partnerID=8YFLogxK

U2 - 10.1172/JCI71101

DO - 10.1172/JCI71101

M3 - Article

VL - 124

SP - 491

EP - 498

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -